Analysis of the key themes driving M&A activity reveals that big data accounted for 3 pharmaceutical deals announced in Q2 2023, worth a total value of $800m. The $800m acquisition of Premier by OMNIA Partners was the industry’s largest disclosed deal. The big data landscape is rapidly evolving and pharma companies are increasingly integrating big data analytics into their value chains. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q2 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations.  Buy the report here.

The top-ranked financial advisors supporting these M&A deals in Q2 2023 were Bank of America; Barclays; Canaccord Genuity Group with 1, 1, 1 deals respectively.

The top-ranked legal advisors supporting these M&A deals in Q2 2023 were CMS Legal Services EEIG; Gibson, Dunn & Crutcher; Hogan Lovells International with 1, 1, 1 deals respectively.

For further understanding of Pharmaceuticals Industry M&A Deals by Top Themes in Q2 2023 – Thematic Intelligence, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.